Further, bi-allelic loss of SETD2, or mutations rendering the protein catalytically inactive, result in loss of H3K36me3 in ccRCC-derived cells and tumors [21, 32, 33]. The gene discussed is SETD2; the disease is nonpapillary renal cell carcinoma.